Symbols / BIOA Stock $18.36 -6.37% BioAge Labs, Inc.
BIOA (Stock) Chart
About
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Stock Fundamentals
Scroll to Statements| Market Cap | 815.14M | Enterprise Value | 539.27M | Income | -80.61M | Sales | 8.99M | Book/sh | 7.28 | Cash/sh | 6.33 |
| Dividend Yield | — | Payout | 0.00% | Employees | 60 | IPO | — | P/E | 1.58 | Forward P/E | -6.61 |
| PEG | — | P/S | 90.62 | P/B | 2.52 | P/C | — | EV/EBITDA | -5.83 | EV/Sales | 59.95 |
| Quick Ratio | 14.06 | Current Ratio | 14.24 | Debt/Eq | 2.04 | LT Debt/Eq | — | EPS (ttm) | -2.24 | EPS next Y | -2.78 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-05 | ROA | -17.76% | ROE | -27.09% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | -9.23% | Profit Margin | 0.00% | Shs Outstand | 44.40M | Shs Float | 37.01M | Short Float | 3.99% |
| Short Ratio | 2.51 | Short Interest | — | 52W High | 24.00 | 52W Low | 3.67 | Beta | — | Avg Volume | 559.14K |
| Volume | 390.62K | Target Price | $53.33 | Recom | Buy | Prev Close | $19.61 | Price | $18.36 | Change | -6.37% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-27 | init | Needham | — → Buy | $50 |
| 2026-03-10 | main | Citigroup | Buy → Buy | $52 |
| 2026-02-25 | init | Oppenheimer | — → Outperform | $60 |
| 2026-02-18 | up | Jefferies | Hold → Buy | $62 |
| 2026-01-27 | init | Piper Sandler | — → Overweight | $73 |
| 2025-12-08 | up | Morgan Stanley | Underweight → Equal-Weight | $12 |
| 2025-10-29 | main | Citigroup | Buy → Buy | $15 |
| 2025-10-22 | up | Citigroup | Neutral → Buy | $10 |
| 2025-03-24 | main | Citigroup | Neutral → Neutral | $5 |
| 2025-02-28 | init | William Blair | — → Market Perform | — |
| 2024-12-09 | down | Citigroup | Buy → Neutral | $7 |
| 2024-12-09 | down | Jefferies | Buy → Hold | $7 |
- BioAge Labs (BIOA) Stock: Should You Take Exposure (Volatility Increases) 2026-04-20 - Global Trading Community - UBND thành phố Hải Phòng Mon, 20 Apr 2026 14
- An oral inflammation drug cut a heart-risk marker 85% in BioAge trial - Stock Titan ue, 21 Apr 2026 11
- Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know - Yahoo Finance ue, 21 Apr 2026 13
- BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans - Benzinga ue, 21 Apr 2026 15
- BIOA (BioAge Labs Inc.) Q4 2025 loss narrows more than expected, shares climb 8.83 percent on investor enthusiasm. - Management Guidance - Xã Vĩnh Công Wed, 22 Apr 2026 18
- $BIOA stock is down 9% today. Here's what we see in our data. - Quiver Quantitative Fri, 10 Apr 2026 19
- Jefferies reiterates Buy on BioAge Labs stock citing NLRP3 progress - Investing.com ue, 24 Mar 2026 07
- Should I buy BioAge Labs, Inc. (BIOA) - Zacks Investment Research ue, 07 Apr 2026 07
- Directors and auditor up for approval at BioAge Labs (NASDAQ: BIOA) 2026 meeting - Stock Titan ue, 21 Apr 2026 20
- Jefferies reiterates BioAge Labs stock rating on dose data By Investing.com - Investing.com Nigeria ue, 21 Apr 2026 20
- [ARS] BioAge Labs, Inc. SEC Filing - Stock Titan ue, 21 Apr 2026 20
- $BIOA stock is up 15% today. Here's what we see in our data. - Quiver Quantitative Mon, 16 Mar 2026 07
- BioAge CEO's April 16 fireside chat will stream live online - Stock Titan Mon, 13 Apr 2026 07
- BioAge Labs (NASDAQ: BIOA) CMO exercises options, sells 8,820 shares at $17.81 - Stock Titan Fri, 03 Apr 2026 07
- $BIOA stock is up 17% today. Here's what we see in our data. - Quiver Quantitative Mon, 12 Jan 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
8.99
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
8.99
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
101.78
+30.16%
|
78.19
+61.56%
|
48.40
+21.09%
|
39.97
|
| Research And Development |
|
73.97
+25.29%
|
59.04
+74.22%
|
33.89
+11.02%
|
30.52
|
| Selling General And Administration |
|
27.81
+45.16%
|
19.16
+32.00%
|
14.51
+53.64%
|
9.45
|
| General And Administrative Expense |
|
27.81
+45.16%
|
19.16
+32.00%
|
14.51
+53.64%
|
9.45
|
| Other Gand A |
|
27.81
+45.16%
|
19.16
+32.00%
|
14.51
+53.64%
|
9.45
|
| Total Expenses |
|
101.78
+30.16%
|
78.19
+61.56%
|
48.40
+21.09%
|
39.97
|
| Operating Income |
|
-92.78
-18.65%
|
-78.19
-61.56%
|
-48.40
-21.09%
|
-39.97
|
| Total Operating Income As Reported |
|
-92.78
-18.65%
|
-78.19
-61.56%
|
-48.40
-21.09%
|
-39.97
|
| EBITDA |
|
-79.69
-16.22%
|
-68.58
-22.68%
|
-55.90
-42.05%
|
-39.35
|
| Normalized EBITDA |
|
-79.48
-16.20%
|
-68.40
-49.32%
|
-45.81
-16.34%
|
-39.38
|
| Reconciled Depreciation |
|
0.21
+27.54%
|
0.17
+3.09%
|
0.16
+25.58%
|
0.13
|
| EBIT |
|
-79.91
-16.24%
|
-68.74
-22.62%
|
-56.06
-41.99%
|
-39.48
|
| Total Unusual Items |
|
-0.21
-20.90%
|
-0.18
+98.25%
|
-10.09
-43973.91%
|
0.02
|
| Total Unusual Items Excluding Goodwill |
|
-0.21
-20.90%
|
-0.18
+98.25%
|
-10.09
-43973.91%
|
0.02
|
| Special Income Charges |
|
0.00
+100.00%
|
-0.25
|
0.00
|
—
|
| Other Special Charges |
|
—
|
0.25
|
—
|
—
|
| Net Income |
|
-80.61
-13.35%
|
-71.11
-11.36%
|
-63.85
-60.75%
|
-39.72
|
| Pretax Income |
|
-80.61
-13.35%
|
-71.11
-11.36%
|
-63.85
-60.75%
|
-39.72
|
| Net Non Operating Interest Income Expense |
|
12.39
+70.60%
|
7.26
+235.41%
|
-5.36
-2494.20%
|
0.22
|
| Interest Expense Non Operating |
|
0.70
-70.55%
|
2.37
-69.63%
|
7.79
+3134.02%
|
0.24
|
| Net Interest Income |
|
12.39
+70.60%
|
7.26
+235.41%
|
-5.36
-2494.20%
|
0.22
|
| Interest Expense |
|
0.70
-70.55%
|
2.37
-69.63%
|
7.79
+3134.02%
|
0.24
|
| Interest Income Non Operating |
|
13.09
+35.90%
|
9.63
+296.09%
|
2.43
+422.80%
|
0.47
|
| Interest Income |
|
13.09
+35.90%
|
9.63
+296.09%
|
2.43
+422.80%
|
0.47
|
| Other Income Expense |
|
-0.21
-20.90%
|
-0.18
+98.25%
|
-10.09
-43973.91%
|
0.02
|
| Gain On Sale Of Security |
|
-0.21
-393.15%
|
0.07
+100.72%
|
-10.09
-43973.91%
|
0.02
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-80.61
-13.35%
|
-71.11
-11.36%
|
-63.85
-60.75%
|
-39.72
|
| Net Income From Continuing Operation Net Minority Interest |
|
-80.61
-13.35%
|
-71.11
-11.36%
|
-63.85
-60.75%
|
-39.72
|
| Net Income From Continuing And Discontinued Operation |
|
-80.61
-13.35%
|
-71.11
-11.36%
|
-63.85
-60.75%
|
-39.72
|
| Net Income Continuous Operations |
|
-80.61
-13.35%
|
-71.11
-11.36%
|
-63.85
-60.75%
|
-39.72
|
| Normalized Income |
|
-80.39
-13.34%
|
-70.93
-31.93%
|
-53.76
-35.27%
|
-39.74
|
| Net Income Common Stockholders |
|
-80.61
-13.35%
|
-71.11
-11.36%
|
-63.85
-60.75%
|
-39.72
|
| Diluted EPS |
|
—
|
-6.63
-108.91%
|
-3.17
+86.64%
|
-23.76
|
| Basic EPS |
|
—
|
-6.63
-108.91%
|
-3.17
+86.64%
|
-23.76
|
| Basic Average Shares |
|
—
|
10.73
-46.69%
|
20.12
+1103.51%
|
1.67
|
| Diluted Average Shares |
|
—
|
10.73
-46.69%
|
20.12
+1103.51%
|
1.67
|
| Diluted NI Availto Com Stockholders |
|
-80.61
-13.35%
|
-71.11
-11.36%
|
-63.85
-60.75%
|
-39.72
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
294.89
-17.68%
|
358.23
+1281.86%
|
25.92
-8.81%
|
28.43
|
| Current Assets |
|
286.79
-19.69%
|
357.10
+1311.14%
|
25.31
-9.72%
|
28.03
|
| Cash Cash Equivalents And Short Term Investments |
|
281.10
-20.67%
|
354.35
+1537.17%
|
21.64
-21.70%
|
27.64
|
| Cash And Cash Equivalents |
|
188.89
-46.69%
|
354.35
+1537.17%
|
21.64
-21.70%
|
27.64
|
| Other Short Term Investments |
|
92.21
|
0.00
|
—
|
—
|
| Receivables |
|
0.77
|
0.00
|
—
|
—
|
| Accounts Receivable |
|
0.77
|
0.00
|
—
|
—
|
| Restricted Cash |
|
—
|
0.00
-100.00%
|
3.31
|
0.00
|
| Other Current Assets |
|
4.93
+78.87%
|
2.75
+689.11%
|
0.35
-9.59%
|
0.39
|
| Total Non Current Assets |
|
8.10
+615.83%
|
1.13
+83.01%
|
0.62
+54.89%
|
0.40
|
| Net PPE |
|
3.75
+373.83%
|
0.79
+52.70%
|
0.52
+38.50%
|
0.37
|
| Gross PPE |
|
4.23
+264.03%
|
1.16
+24.01%
|
0.94
+49.44%
|
0.63
|
| Accumulated Depreciation |
|
-0.48
-29.92%
|
-0.37
+11.46%
|
-0.42
-65.61%
|
-0.25
|
| Properties |
|
0.00
|
0.00
|
—
|
—
|
| Machinery Furniture Equipment |
|
0.24
+104.27%
|
0.12
-68.88%
|
0.38
+23.28%
|
0.30
|
| Construction In Progress |
|
0.02
-87.50%
|
0.18
|
0.00
|
—
|
| Other Properties |
|
3.81
+338.20%
|
0.87
+54.90%
|
0.56
+74.22%
|
0.32
|
| Leases |
|
0.16
|
0.00
|
—
|
—
|
| Investments And Advances |
|
4.13
+4032.00%
|
0.10
+0.00%
|
0.10
|
0.00
|
| Other Investments |
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
|
0.00
|
| Other Non Current Assets |
|
0.22
-10.00%
|
0.24
|
—
|
0.03
|
| Total Liabilities Net Minority Interest |
|
22.84
-34.95%
|
35.11
-82.39%
|
199.32
+41.37%
|
140.99
|
| Current Liabilities |
|
20.14
-27.50%
|
27.77
-52.25%
|
58.17
+892.46%
|
5.86
|
| Payables And Accrued Expenses |
|
10.63
-20.26%
|
13.33
+58.41%
|
8.41
+49.71%
|
5.62
|
| Payables |
|
2.67
+33.97%
|
2.00
+6.97%
|
1.87
-17.47%
|
2.26
|
| Accounts Payable |
|
2.67
+33.97%
|
2.00
+6.97%
|
1.87
-17.47%
|
2.26
|
| Current Accrued Expenses |
|
7.96
-29.81%
|
11.33
+73.06%
|
6.55
+94.91%
|
3.36
|
| Current Debt And Capital Lease Obligation |
|
3.23
-47.92%
|
6.20
-86.23%
|
45.05
+20756.94%
|
0.22
|
| Current Debt |
|
2.65
-55.87%
|
6.00
-86.62%
|
44.86
+26760.48%
|
0.17
|
| Other Current Borrowings |
|
2.65
-55.87%
|
6.00
-86.62%
|
44.86
+26760.48%
|
0.17
|
| Current Capital Lease Obligation |
|
0.58
+188.12%
|
0.20
+4.12%
|
0.19
+295.92%
|
0.05
|
| Current Deferred Liabilities |
|
5.75
-26.48%
|
7.83
+136.22%
|
3.31
|
0.00
|
| Current Deferred Revenue |
|
5.75
-26.48%
|
7.83
+136.22%
|
3.31
|
0.00
|
| Other Current Liabilities |
|
0.53
+25.90%
|
0.42
-69.98%
|
1.39
+5687.50%
|
0.02
|
| Total Non Current Liabilities Net Minority Interest |
|
2.70
-63.18%
|
7.33
-94.81%
|
141.15
+4.46%
|
135.13
|
| Long Term Debt And Capital Lease Obligation |
|
2.33
-6.87%
|
2.50
-69.49%
|
8.20
+264.17%
|
2.25
|
| Long Term Debt |
|
—
|
2.50
-69.49%
|
8.20
+264.17%
|
2.25
|
| Long Term Capital Lease Obligation |
|
2.33
|
0.00
|
—
|
—
|
| Non Current Deferred Liabilities |
|
0.00
-100.00%
|
4.67
|
0.00
|
—
|
| Non Current Deferred Revenue |
|
0.00
-100.00%
|
4.67
|
0.00
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
0.00
-100.00%
|
132.72
+0.00%
|
132.72
|
| Stockholders Equity |
|
272.05
-15.81%
|
323.13
+286.35%
|
-173.40
-54.05%
|
-112.56
|
| Common Stock Equity |
|
272.05
-15.81%
|
323.13
+286.35%
|
-173.40
-54.05%
|
-112.56
|
| Capital Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
—
|
—
|
| Share Issued |
|
37.39
+4.29%
|
35.85
+4.93%
|
34.17
+0.00%
|
34.17
|
| Ordinary Shares Number |
|
37.39
+4.29%
|
35.85
+4.93%
|
34.17
+0.00%
|
34.17
|
| Additional Paid In Capital |
|
605.19
+5.12%
|
575.69
+6970.66%
|
8.14
+58.96%
|
5.12
|
| Retained Earnings |
|
-333.42
-31.88%
|
-252.81
-39.13%
|
-181.70
-54.18%
|
-117.85
|
| Gains Losses Not Affecting Retained Earnings |
|
0.28
+13.47%
|
0.24
+49.39%
|
0.16
-1.80%
|
0.17
|
| Other Equity Adjustments |
|
0.28
+13.47%
|
0.24
+49.39%
|
0.16
-1.80%
|
0.17
|
| Total Equity Gross Minority Interest |
|
272.05
-15.81%
|
323.13
+286.35%
|
-173.40
-54.05%
|
-112.56
|
| Total Capitalization |
|
272.05
-16.45%
|
325.63
+297.12%
|
-165.19
-49.76%
|
-110.31
|
| Working Capital |
|
266.65
-19.03%
|
329.33
+1102.15%
|
-32.86
-248.23%
|
22.17
|
| Invested Capital |
|
274.70
-17.17%
|
331.63
+375.58%
|
-120.34
-9.26%
|
-110.14
|
| Total Debt |
|
5.56
-36.12%
|
8.70
-83.66%
|
53.25
+2057.70%
|
2.47
|
| Net Debt |
|
—
|
—
|
31.41
|
—
|
| Capital Lease Obligations |
|
2.91
+1341.58%
|
0.20
+4.12%
|
0.19
+295.92%
|
0.05
|
| Net Tangible Assets |
|
272.05
-15.81%
|
323.13
+286.35%
|
-173.40
-54.05%
|
-112.56
|
| Tangible Book Value |
|
272.05
-15.81%
|
323.13
+286.35%
|
-173.40
-54.05%
|
-112.56
|
| Available For Sale Securities |
|
4.03
|
—
|
—
|
—
|
| Derivative Product Liabilities |
|
0.37
+137.18%
|
0.16
-31.88%
|
0.23
+49.67%
|
0.15
|
| Investmentin Financial Assets |
|
4.03
|
0.00
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-81.63
-58.43%
|
-51.52
-37.90%
|
-37.36
-3.26%
|
-36.18
|
| Cash Flow From Continuing Operating Activities |
|
-81.63
-58.43%
|
-51.52
-37.90%
|
-37.36
-3.26%
|
-36.18
|
| Net Income From Continuing Operations |
|
-80.61
-13.35%
|
-71.11
-11.36%
|
-63.85
-60.75%
|
-39.72
|
| Depreciation Amortization Depletion |
|
0.21
+27.54%
|
0.17
+3.09%
|
0.16
+25.58%
|
0.13
|
| Depreciation |
|
0.21
+27.54%
|
0.17
+3.09%
|
0.16
+25.58%
|
0.13
|
| Depreciation And Amortization |
|
0.21
+27.54%
|
0.17
+3.09%
|
0.16
+25.58%
|
0.13
|
| Other Non Cash Items |
|
-1.33
-229.24%
|
1.03
-84.14%
|
6.51
+6413.00%
|
0.10
|
| Stock Based Compensation |
|
11.69
+67.52%
|
6.98
+131.40%
|
3.02
+18.74%
|
2.54
|
| Operating Gains Losses |
|
0.24
+2.16%
|
0.23
-97.70%
|
10.09
+43973.91%
|
-0.02
|
| Gain Loss On Investment Securities |
|
0.21
+393.15%
|
-0.07
-100.72%
|
10.09
+43973.91%
|
-0.02
|
| Gain Loss On Sale Of PPE |
|
0.02
-58.18%
|
0.06
|
0.00
|
—
|
| Change In Working Capital |
|
-11.83
-205.83%
|
11.18
+66.56%
|
6.71
+744.03%
|
0.80
|
| Change In Receivables |
|
-0.77
|
0.00
|
—
|
—
|
| Changes In Account Receivables |
|
-0.77
|
0.00
|
—
|
—
|
| Change In Prepaid Assets |
|
-1.71
+28.77%
|
-2.40
-6600.00%
|
0.04
+223.33%
|
-0.03
|
| Change In Payables And Accrued Expense |
|
-2.62
-156.62%
|
4.63
+38.95%
|
3.33
+605.07%
|
0.47
|
| Change In Accrued Expense |
|
-3.41
-173.73%
|
4.63
+24.14%
|
3.73
+815.55%
|
-0.52
|
| Change In Payable |
|
0.79
+13033.33%
|
0.01
+101.53%
|
-0.39
-139.54%
|
0.99
|
| Change In Account Payable |
|
0.79
+13033.33%
|
0.01
+101.53%
|
-0.39
-139.54%
|
0.99
|
| Change In Other Working Capital |
|
-6.75
-173.43%
|
9.19
+177.30%
|
3.31
|
—
|
| Change In Other Current Assets |
|
0.02
+110.00%
|
-0.24
-1060.00%
|
0.03
-92.90%
|
0.35
|
| Investing Cash Flow |
|
-95.22
-25915.30%
|
-0.37
-37.59%
|
-0.27
-158.25%
|
-0.10
|
| Cash Flow From Continuing Investing Activities |
|
-95.22
-25915.30%
|
-0.37
-37.59%
|
-0.27
-158.25%
|
-0.10
|
| Net PPE Purchase And Sale |
|
-0.72
-96.45%
|
-0.37
-120.48%
|
-0.17
-61.17%
|
-0.10
|
| Purchase Of PPE |
|
-0.72
-96.45%
|
-0.37
-120.48%
|
-0.17
-61.17%
|
-0.10
|
| Capital Expenditure |
|
-0.72
-96.45%
|
-0.37
-120.48%
|
-0.17
-61.17%
|
-0.10
|
| Net Investment Purchase And Sale |
|
-94.50
|
0.00
+100.00%
|
-0.10
|
0.00
|
| Purchase Of Investment |
|
-154.75
|
0.00
+100.00%
|
-0.10
|
0.00
|
| Sale Of Investment |
|
60.25
|
0.00
|
—
|
—
|
| Financing Cash Flow |
|
11.47
-96.99%
|
381.20
+990.98%
|
34.94
+1298.20%
|
2.50
|
| Cash Flow From Continuing Financing Activities |
|
11.47
-96.99%
|
381.20
+990.98%
|
34.94
+1298.20%
|
2.50
|
| Net Issuance Payments Of Debt |
|
-6.00
+0.00%
|
-6.00
-117.14%
|
35.00
+1300.00%
|
2.50
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
36.00
+1340.00%
|
2.50
|
| Repayment Of Debt |
|
-6.00
+0.00%
|
-6.00
-500.00%
|
-1.00
|
0.00
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
12.50
+400.00%
|
2.50
|
| Long Term Debt Payments |
|
-6.00
+0.00%
|
-6.00
-500.00%
|
-1.00
|
0.00
|
| Net Long Term Debt Issuance |
|
-6.00
+0.00%
|
-6.00
-152.17%
|
11.50
+360.00%
|
2.50
|
| Short Term Debt Issuance |
|
—
|
0.00
-100.00%
|
23.50
|
0.00
|
| Net Short Term Debt Issuance |
|
—
|
0.00
-100.00%
|
23.50
|
0.00
|
| Net Common Stock Issuance |
|
17.16
-92.26%
|
221.62
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
0.71
+12.62%
|
0.63
+15750.00%
|
0.00
-90.91%
|
0.04
|
| Net Other Financing Charges |
|
-0.40
+92.09%
|
-5.05
-7922.22%
|
-0.06
-40.00%
|
-0.04
|
| Changes In Cash |
|
-165.37
-150.22%
|
329.31
+12355.71%
|
-2.69
+92.05%
|
-33.78
|
| Effect Of Exchange Rate Changes |
|
-0.09
-207.41%
|
0.08
|
0.00
-100.00%
|
0.25
|
| Beginning Cash Position |
|
354.35
+1319.84%
|
24.96
-9.72%
|
27.64
-54.82%
|
61.18
|
| End Cash Position |
|
188.89
-46.69%
|
354.35
+1319.84%
|
24.96
-9.72%
|
27.64
|
| Free Cash Flow |
|
-82.35
-58.70%
|
-51.89
-38.26%
|
-37.53
-3.43%
|
-36.28
|
| Interest Paid Supplemental Data |
|
0.61
-56.97%
|
1.42
+22.94%
|
1.16
+795.35%
|
0.13
|
| Common Stock Issuance |
|
17.16
-92.26%
|
221.62
|
0.00
|
—
|
| Issuance Of Capital Stock |
|
17.16
-95.62%
|
391.62
|
0.00
|
—
|
| Net Preferred Stock Issuance |
|
0.00
-100.00%
|
170.00
|
0.00
|
—
|
| Preferred Stock Issuance |
|
0.00
-100.00%
|
170.00
|
0.00
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-03 View
- 10-K2026-03-24 View
- 8-K2026-03-24 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-02-19 View
- 42026-02-19 View
- 42026-02-19 View
- 42026-02-19 View
- 42026-02-19 View
- 42026-02-03 View
- 42026-02-03 View
- 8-K2026-01-22 View
- 42026-01-21 View
- 8-K2026-01-20 View
- 42026-01-15 View
- 42026-01-15 View
- 8-K2026-01-12 View
- 42026-01-06 View
- 42025-12-11 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|